Erlmeier, Franziska and Steffens, Sandra and Stoehr, Christine and Herrmann, Edwin and Polifka, Iris and Agaimy, Abbas and Trojan, Lutz and Stroebel, Philipp and Becker, Frank and Wuelfing, Christian and Barth, Peter and Stoeckle, Michael and Staehler, Michael and Stief, Christian and Haferkamp, Axel and Hohenfellner, Markus and Macher-Goeppinger, Stephan and Wullich, Bernd and Noldus, Joachim and Brenner, Walburgis and Roos, Frederik C. and Walter, Bernhard and Otto, Wolfgang and Burger, Maximilian and Schrader, Andres Jan and Hartmann, Arndt and Vanyi, Philipp (2021) Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. CLINICAL GENITOURINARY CANCER, 19 (1). 53-+. ISSN 1558-7673, 1938-0682
Full text not available from this repository. (Request a copy)Abstract
Understanding the impact of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) expression becomes increasingly important in renal cell carcinoma (RCC) owing to increasing therapeutic implications. However, little is known in non -clear-cell RCC about the relevance of those immune checkpoint surrogates. Here, we suggest that PD-1/PD-L1 expression in papillary RCC does not have prognostic impact, neither for type 1 nor type 2. However, in advanced disease, further evaluation according to PD-1/PD-L1 is warranted. Background: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods: Patients' sample collection was a joint collaboration of the nationwide PANZAR consortium -a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results: Of 374 pRCC specimens, 204 type 1 and 97 type 2 were evaluable for PD-1 and PD-L1 expression analysis. In total, PD-1 and PD-L1 expression were found in 8 (4.9%) of 162 and 12 (7.2%) of 166 evaluable pRCC type 1 specimens. Comparably, PD-1 and PD-L1 expression were found in 2 (2.4%) of 83 and 5 (6.2%) of 81 evaluable pRCC type 2 specimens. Hardly any clinically relevant associations between PD-1 and PD-L1 positivity and clinicopathologic or clinical courses were observed, neither in pRCC type 1 nor type 2. Conclusion: The analysis of a large pRCC cohort from a multicenter consortium revealed no impact of PD-1/PD-L1 expression on prognosis in patients with pRCC with predominantly limited disease status, neither for type 1 nor type 2. However, the impact of PD-1 and PD-L1 in more advanced pRCC disease needs further elucidation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METASTATIC SITES; IMMUNOHISTOCHEMISTRY; NIVOLUMAB; SURVIVAL; MEMBER; B7-H1; Non-clear-cell-renal carcinoma; Papillary renal cell; PD-1; PD-L1; Renal cell carcinoma |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 Sep 2022 13:12 |
| Last Modified: | 27 Sep 2022 13:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48098 |
Actions (login required)
 |
View Item |
